Suppr超能文献

HIV-PASS(疼痛和悲伤支持):一项行为健康干预措施对艾滋病毒感染者、慢性疼痛和抑郁症患者因疼痛而产生的干扰的随机对照试验。

HIV-PASS (Pain and Sadness Support): Randomized Controlled Trial of a Behavioral Health Intervention for Interference Due to Pain in People Living With HIV, Chronic Pain, and Depression.

机构信息

From the Departments of Psychiatry and Human Behavior (Uebelacker, Pinkston, Caviness, Herman, Abrantes) and Family Medicine (Uebelacker, Weisberg), Alpert Medical School of Brown University; Behavioral Medicine and Addictions Research (Uebelacker, Anderson, Caviness, Herman, Abrantes, Stein), Butler Hospital; Department of Medicine (Pinkston), Alpert Medical School of Brown University; Lifespan Physicians Group (Pinkston), The Miriam Hospital, Providence, Rhode Island; Department of Medicine (Busch, Baker), Hennepin Healthcare; Department of Medicine (Busch, Baker), University of Minnesota, Minneapolis, Minnesota; VA Boston Healthcare System (Weisberg); Department of Psychiatry (Weisberg), Boston University School of Medicine; and Department of Health Law, Policy and Management(Stein), Boston University School of Public Health, Boston, Massachusetts.

出版信息

Psychosom Med. 2023 Apr 1;85(3):250-259. doi: 10.1097/PSY.0000000000001172. Epub 2023 Feb 3.

Abstract

OBJECTIVE

This study aimed to determine whether HIV-Pain and Sadness Support (HIV-PASS), a collaborative behavioral health intervention based on behavioral activation, is associated with decreased pain-related interference with daily activities, depression, and other outcomes in people living with HIV.

METHODS

We conducted a three-site clinical trial ( n = 187) in which we randomly assigned participants to receive either HIV-PASS or health education control condition. In both conditions, participants received seven intervention sessions, comprising an initial in-person joint meeting with the participant, their HIV primary care provider and a behavioral health specialist, and six, primarily telephone-based, meetings with the behavioral health specialist and participant. The intervention period lasted 3 months, and follow-up assessments were conducted for an additional 9 months.

RESULTS

Compared with health education, HIV-PASS was associated with significantly lower pain-related interference with daily activities at the end of month 3 (our primary outcome; b = -1.31, 95% confidence interval = -2.28 to -0.34). We did not observe other differences between groups at 3 months in secondary outcomes that included worst or average pain in the past week, depression symptoms, anxiety, and perceived overall mental and physical health. There were no differences between groups on any outcomes at 12 months after enrollment.

CONCLUSIONS

A targeted intervention can have positive effects on pain interference. At the end of intervention, effects we found were in a clinically significant range. However, effects diminished once the intervention period ended.

TRIAL REGISTRATION

ClinicalTrials.gov NCT02766751.

摘要

目的

本研究旨在确定基于行为激活的合作行为健康干预措施 HIV-Pain 和 Sadness Support(HIV-PASS)是否与减轻 HIV 感染者的疼痛相关活动障碍、抑郁等结果相关。

方法

我们进行了一项三站点临床试验(n=187),随机分配参与者接受 HIV-PASS 或健康教育对照条件。在两种情况下,参与者都接受了七次干预会议,包括与参与者、他们的 HIV 初级保健提供者和行为健康专家的初始联合面对面会议,以及六次主要基于电话的与行为健康专家和参与者的会议。干预期持续 3 个月,随后进行了额外 9 个月的随访评估。

结果

与健康教育相比,HIV-PASS 在 3 个月时与疼痛相关的日常活动障碍显著降低(我们的主要结局;b=-1.31,95%置信区间=-2.28 至-0.34)。我们没有在 3 个月时观察到其他次要结局(包括过去一周的最痛或平均疼痛、抑郁症状、焦虑和整体心理和身体健康的感知)存在组间差异。在招募后 12 个月,两组在任何结局上均无差异。

结论

有针对性的干预措施可以对疼痛障碍产生积极影响。在干预结束时,我们发现的效果处于临床显著范围内。然而,一旦干预期结束,效果就会减弱。

试验注册

ClinicalTrials.gov NCT02766751。

相似文献

4
在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
行为修正干预对初级保健中无法用医学解释的症状:系统评价和经济评估。
Health Technol Assess. 2020 Sep;24(46):1-490. doi: 10.3310/hta24460.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验